CoraVie Medical

Executive Summary

CoraVie Medical is an early-stage medical device company developing an implantable continuous blood pressure monitor to provide physicians with long-term, clinically accurate data for managing chronic hypertension. Founded in 2017 and based in Eden Prairie, Minnesota, the company aims to overcome the limitations of traditional home monitoring by offering a patient-independent solution. Currently in the pre-clinical stage, CoraVie is focused on advancing its technology through regulatory and clinical development. The implantable sensor is designed to capture real-time blood pressure readings, enabling better treatment decisions and improved outcomes for the millions of patients with uncontrolled hypertension. As a private company with no disclosed funding or revenue, CoraVie relies on strategic partnerships and future capital raises to progress toward first-in-human studies and eventual commercialization.

Upcoming Catalysts (preview)

• Q3 2026Pre-IDE Submission to FDA70% success
• Q4 2026Series A Financing Round60% success
• Q1 2027First-in-Human Clinical Trial Initiation50% success